论文部分内容阅读
目的：探讨预测干扰素治疗慢性丙型肝炎（ＣＨＣ）疗效的临床上适用、简便、易行的指标。方法：对采用干扰素（ＩＦＮα－１ｂ）治疗３２例ＣＨＣ临床资料进行观察，包括治疗前后肝功能（ＡＬＴ、ＳＢ、ＧＧＴ）、抗－ＨＣＶＯＤ水平、ＨＣＶ基因型、ＨＣＶＲＮＡ、ＳＩＬ－２Ｒ、β２－ＭＧ等，治疗结束时有效者为肝功能复常同时ＨＣＶＲＮＡ阴转，其余反应模式均为无效者。结果：ＨＣＶ基因型为Ⅲ型患者疗效（５／１０）明显高于Ⅱ型（２／１９）（Ｐ＜０．０５），有效者治疗前血清抗—ＨＣＶＯＤ明显低于无效者（Ｐ＜０．０５），治疗后有效者β２－ＭＧ升高水平（３．４５±１．０８）ｍｇ／Ｌ明显高于无效者（１．３３±０．９５）ｍｇ／Ｌ（Ｐ＜０．０５），而两者治疗前ＡＬＴ、ＳＢ、ＧＧＴ、ＩｇＭ、β２－ＭＧ患者的年龄无明显差别（Ｐ＞０．０５）。结论：感染ＨＣＶ基因型，治疗前抗—ＨＣＶＯＤ水平及治疗后β２－ＭＧ变化对预测ＩＦＮ治疗ＣＨＣ疗效有一定参考价值。
Objective: To investigate the clinically applicable, simple and easy-to-predict indicators for predicting the efficacy of interferon in the treatment of chronic hepatitis C (CHC). Methods: The clinical data of 32 cases of CHC treated with interferon (IFNα-1b) were observed, including liver function (ALT, SB, GGT), anti-HCVOD, HCV genotype, HCVRNA, SIL- MG, effective at the end of treatment for the liver function and HCV RNA negative at the same time, the rest of the reaction mode are ineffective. Results: The HCV genotype Ⅲ was significantly higher in patients with type Ⅲ than in type Ⅱ (2/19) (P <0.05) .05), the effective level of β2-MG (3.45 ± 1.08) mg / L after treatment was significantly higher than that of ineffective (1.33 ± 0.95) mg / L (P <0.05) , While there was no significant difference in the age of ALT, SB, GGT, IgM and β2-MG between the two groups before treatment (P> 0.05). CONCLUSIONS: HCV genotypes, anti-HCV level before treatment and changes of β2-MG after treatment have some reference value for predicting the therapeutic effect of IFN on CHC.